Aspo Plc
29.12.2025 17:30:00 CET | Globenewswire | Press release
Aspo Plc: Share repurchase 29.12.2025
Aspo Plc: Share repurchase 29.12.2025
| Aspo Plc | ANNOUNCEMENT | 29.12.2025 |
| Aspo Plc: Share repurchase 29.12.2025 | ||
| In the Helsinki Stock Exchange | ||
| Trade date | 29.12.2025 | |
| Bourse trade | Buy | |
| Share | ASPO | |
| Amount | 2 500 | Shares |
| Average price/ share | 6,4720 | EUR |
| Total cost | 16 180,00 | EUR |
| Aspo Plc now holds a total of 105 500 shares | ||
| including the shares repurchased on 29.12.2025 | ||
| The share buybacks are executed in compliance with Regulation | ||
| No. 596/2014 of the European Parliament and Council (MAR) Article 5 | ||
| and the Commission Delegated Regulation (EU) 2016/1052. | ||
| On behalf of Aspo Plc | ||
| Nordea Bank Oyj | ||
| Sami Huttunen | Ilari Isomäki | |
| For more information, please contact: | ||
| Erkka Repo, CFO, Aspo Plc, tel. +358 40 5827 971, erkka.repo@aspo.com | ||
| www.aspo.com | ||
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Sonoco Products Company25.8.2026 19:00:00 CEST | Press release
Sonoco to Increase Paperboard Prices in EMEA Region
Park Street A/S25.8.2026 18:47:21 CEST | Press release
Park Street A/S – Park Street Interim Report Half Year 2026
2026 China International Fair for Trade in Services (CIFTIS)25.8.2026 17:10:17 CEST | Press release
Overseas session of 2026 CIFTIS held in Kristiansund, Norway
Volta Finance Limited25.8.2026 16:46:13 CEST | Press release
Volta Finance Limited Net Asset Value(s) as at 31 July 2026
Zymeworks Inc.25.8.2026 16:23:13 CEST | Press release
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom